norfloxacin has been researched along with Encephalopathy, Hepatic in 3 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 9.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| "Two hundred and sixty two cirrhotic patients with ascites and a previous episode of SBP were assigned randomly to receive either 1200 mg rifaximin or 400 mg of norfloxacin daily for 6 months." | 5.22 | Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis. ( Abd-Elsalam, S; Abo Ali, L; Elfert, A; Ibrahim, S; Soliman, S, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elfert, A | 1 |
| Abo Ali, L | 1 |
| Soliman, S | 1 |
| Ibrahim, S | 1 |
| Abd-Elsalam, S | 1 |
| Colle, I | 1 |
| De Keukeleire, K | 1 |
| Pauwels, W | 1 |
| Van Vlierberghe, H | 1 |
| Salmerón, JM | 1 |
| Titó, L | 1 |
| Rimola, A | 1 |
| Mas, A | 1 |
| Navasa, MA | 1 |
| Llach, J | 1 |
| Ginès, A | 1 |
| Ginès, P | 1 |
| Arroyo, V | 1 |
| Rodés, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy and Safety of Rifaximin In The Treatment of HBV Associated Acute-on-Chronic Liver Failure Patients With Mild to Moderate Hepatic Encephalopathy[NCT05786859] | Early Phase 1 | 124 participants (Anticipated) | Interventional | 2023-03-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for norfloxacin and Encephalopathy, Hepatic
| Article | Year |
|---|---|
Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ascites; Bacterial Infections; Cause of Death; Egypt; | 2016 |
Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure.
Topics: Adult; Bacterial Infections; Colistin; Enterobacteriaceae; Female; Gram-Negative Bacteria; Gram-Posi | 1992 |
1 other study available for norfloxacin and Encephalopathy, Hepatic
| Article | Year |
|---|---|
'Hepatic' encephalopathy because of spontaneous mesenterico-caval shunt.
Topics: Anti-Bacterial Agents; Collateral Circulation; Fatty Liver; Female; Gastrointestinal Agents; Hepatic | 2008 |